GLP-1 Medications for Urinary Incontinence
Excess abdominal weight puts pressure on the bladder and pelvic floor muscles, causing or worsening urinary incontinence. GLP-1 weight loss significantly reduces pressure on the pelvic floor, improving or resolving urinary incontinence in many patients. Urinary Incontinence affects approximately 25 million adults in the US, predominantly women, and GLP-1 medications offer a clinically proven treatment option.
Prevalence
approximately 25 million adults in the US, predominantly women
Recommended Medications
2
Treatment Type
GLP-1 Agonist
How GLP-1 Medications Help with Urinary Incontinence
GLP-1 weight loss significantly reduces pressure on the pelvic floor, improving or resolving urinary incontinence in many patients. For patients with urinary incontinence, GLP-1 medications address the underlying metabolic dysfunction that makes weight management difficult. Clinical trials have consistently shown that GLP-1 treatment produces significant improvements in both weight and condition-specific outcomes.
Recommended GLP-1 Medications for Urinary Incontinence
Based on clinical evidence, the following GLP-1 medications are recommended for patients with urinary incontinence:
Semaglutide
Wegovy / Ozempic
Tirzepatide
Zepbound / Mounjaro
Detailed Medication Guides for Urinary Incontinence
Urinary Incontinence & GLP-1 FAQ
Can GLP-1 medications help with urinary incontinence?
Yes. GLP-1 weight loss significantly reduces pressure on the pelvic floor, improving or resolving urinary incontinence in many patients. Clinical evidence supports the use of GLP-1 medications like semaglutide and tirzepatide for patients with urinary incontinence.
Which GLP-1 medication is best for urinary incontinence?
Semaglutide is often the first-line recommendation for urinary incontinence due to its strong clinical evidence. Your provider will evaluate your specific situation to determine the best option.
How much weight can I lose with GLP-1 if I have urinary incontinence?
Weight loss results are generally comparable to clinical trial averages (15-22% of body weight), though individual results vary based on the severity of urinary incontinence and other health factors.
How prevalent is urinary incontinence?
Urinary Incontinence affects approximately 25 million adults in the US, predominantly women. GLP-1 medications represent a significant treatment advancement for patients dealing with this condition alongside excess weight.